Figure 3 Intracranial targeting of high-grade gliomas

Slides:

Advertisements

Similar presentations

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

Advertisements

Samsung Genome Institute Samsung Medical Center

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 1 Cellular processes involved in cancer development

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Molecular subgroups of glioblastoma,

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 2 Three-step approach to the assessment and management

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Management of Glioblastoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Polydactyly L.A. Lettice, et al. Proc. Natl. Acad. Sci. USA 2002; 99(11):

Figure 1 Clinical case study

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

The 3D models in part a are reproduced with permission from Daum, B

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels Lee M. Krug, MD,

Representative CT and PET/CT images of three patients with NSCLCs

Figure 1 Structure of ADAMTS13

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Effects of low-level expression of mutant-template telomerase RNA in MCF-7 breast cancer cells. Effects of low-level expression of mutant-template telomerase.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Representative CT and PET/CT images of three patients with NSCLCs

Representative biodistribution pattern of 111In-CMD-193.

Presentation transcript:

Figure 3 Intracranial targeting of high-grade gliomas by the tumour-specific ABT-806, the parental antibody of ABT-414 Figure 3 | Intracranial targeting of high-grade gliomas by the tumour-specific ABT-806, the parental antibody of ABT-414. a | Single-photon emission computed tomography (SPECT)/CT images and quantification of uptake of 111In-ABT-806 in mice with intracranial U87MGde2-7 tumour implants, which overexpress wild-type EGFR and EGFRvIII. Reprinted from Reilly, E. B. et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol. Cancer Ther. 14, 1141–1151 (2015), with permission from AACR. b | Uptake of 111In-labelled chimeric 806 (the chimeric version of ABT-806) in a patient with high-grade glioma in the right frontal lobes showing blood pool activity only in panel i, followed by increasing uptake by days 3 (arrow in panel ii) and 7 (iii). The uptake is confirmed on axial SPECT imaging (arrow in panel iv) to be at the site of 18F-FDG uptake (v) and the structural abnormality on T1 MRI (vi). Reproduced from Scott, A. M. et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl Acad. Sci. USA 104, 4071–4076 (2007), copyright (2007) National Academy of Sciences, U.S.A. Proc. Natl Acad. Sci. USA 104, 4071–4076 (2007), copyright (2007) National Academy of Sciences, U.S.A. Gan, H. K. et al. (2017) Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.95